Hodgkin lymphoma trials in China

In China 10 Also abroad 155

10 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Where
Beijing, Fuzhou, Guangzhou, Shanghai, Zhengzhou
Age
18 years and over
People
280 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07519772 · EU 2025-523005-15-00
Phase 2Taking people
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Where
Chengdu, Guangzhou, Nanchang, Nanjing, Nantong, Shandong, Shanghai, Tianjin, Zhengzhou
Age
18 years and over
People
270 worldwide
Run by
AstraZeneca
See details and how to joinNCT06526793 · EU 2023-505789-27-00
Phase 1/2Taking people
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Where
Beijing, Guangzhou, Shanghai
Age
12 years and over
People
161 worldwide
Run by
AstraZeneca
See details and how to joinNCT06137144 · EU 2023-506747-42-00
Phase 1/2Not yet taking people in China
PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma
Where
Xuzhou
Age
6 years to 18 years
People
112
Run by
Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT07641010
Phase 1Taking people
A Phase I Study of JLM019 Injection
Where
Beijing
Age
18 years and over
People
115
Run by
Jecho Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07623850
Phase 1Taking people
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
Where
Hangzhou, Xuzhou, Yantai, Zhujiang
Age
18 years and over
People
50 worldwide
Run by
FBD Biologics Limited
See details and how to joinNCT06487624
Phase 3Taking people
A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
Where
Beijing
Age
18 years and over
People
185
Run by
Shanghai Junshi Bioscience Co., Ltd.
See details and how to joinNCT06170489
Phase 1Taking people
A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
Where
Shanghai
Age
18 years to 75 years
People
32
Run by
Ruijin Hospital
See details and how to joinNCT06494371
No phaseTaking people
The Pathogenesis and Prognostic Factors of Lymphoma
Where
Shanghai
People
2,000
Run by
Shanghai Zhongshan Hospital
See details and how to joinNCT06203652
Phase 1/2Taking people
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
Where
Beijing
Age
16 years to 80 years
People
30
Run by
Chinese PLA General Hospital
See details and how to joinNCT02259556